Evidence map›Paper›PMID 36740547›Full record

ArticleDisability and health journal2023

Post-COVID conditions and healthcare utilization among adults with and without disabilities-2021 Porter Novelli FallStyles survey.

Maureen J Miller, Leora R Feldstein, Joseph Holbrook, Ian D Plumb, Emma K Accorsi, Qing C Zhang, Qi Cheng, Jean Y Ko, Valentine Wanga, Stacey Konkle and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disability and health journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Long COVID Among People With Preexisting Disabilities.American journal of public health · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Maureen J MillerCDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging Zoonotic and Infectious Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: yax6@cdc.gov.
Leora R FeldsteinCDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: nqw5@cdc.gov.
Joseph HolbrookDisability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: vzt4@cdc.gov.
Ian D PlumbDivision of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: ydk9@cdc.gov.
Emma K AccorsiDivision of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: vgi0@cdc.gov.
Qing C ZhangDisability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: gso9@cdc.gov.
Qi ChengDisability Science and Program Team, Division of Human Development and Disability, U.S. Centers for Disease Control and Prevention, National Center for Birth Defects and Developmental Disorders, 4770 Buford Hwy NE, Mailstop S106-4, Atlanta, GA, 30341-3717, USA. Electronic address: ycx6@cdc.gov.
Jean Y KoCDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Reproductive Health, National Center for Chronic Diseases Prevention and Health Promotion, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Mailstop S107-1, Atlanta, GA, 30341-3717, USA. Electronic address: fob1@cdc.gov.
Valentine WangaChild Development Studies Team, Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy S106-4, Atlanta, GA 30341-3717, USA; Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: qdy0@cdc.gov.
Stacey KonkleEpidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: qdv8@cdc.gov.
Lina V DimitrovChild Development Studies Team, Division of Human Development and Disability, National Center on Birth Defects and Developmental Disabilities, U.S. Centers for Disease Control and Prevention, 4770 Buford Hwy S106-4, Atlanta, GA 30341-3717, USA; Oak Ridge Institute for Science and Education, U.S. Centers for Disease Control and Prevention Research Participation Programs, P.O. Box 117, Oak Ridge, TN, 37831-0117, USA. Electronic address: qwj7@cdc.gov.
Jeanne BertolliCDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging Zoonotic and Infectious Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: jub7@cdc.gov.
Sharon SaydahCDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA. Electronic address: zle0@cdc.gov.
National Center on Birth Defects and Developmental Disabilities · USNational Center for Immunization and Respiratory Diseases · USCenters for Disease Control and Prevention · USEpidemic Intelligence Service · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdults with disabilities are at increased risk for SARS-CoV-2 infection and severe disease; whether adults with disabilities are at an increased risk for ongoing symptoms after acute SARS-CoV-2 infection is unknown.

objectivesTo estimate the frequency and duration of long-term symptoms (>4 weeks) and health care utilization among adults with and without disabilities who self-report positive or negative SARS-CoV-2 test results.

methodsData from a nationwide survey of 4510 U.S. adults administered from September 24, 2021-October 7, 2021, were analyzed for 3251 (79%) participants who self-reported disability status, symptom(s), and SARS-CoV-2 test results (a positive test or only negative tests). Multivariable models were used to estimate the odds of having ≥1 COVID-19-like symptom(s) lasting >4 weeks by test result and disability status, weighted and adjusted for socio-demographics.

resultsRespondents who tested positive for SARS-CoV-2 had higher odds of reporting ≥1 long-term symptom (with disability: aOR = 4.50 [95% CI: 2.37, 8.54] and without disability: aOR = 9.88 [95% CI: 7.13, 13.71]) compared to respondents testing negative. Among respondents who tested positive, those with disabilities were not significantly more likely to experience long-term symptoms compared to respondents without disabilities (aOR = 1.65 [95% CI: 0.78, 3.50]). Health care utilization for reported symptoms was higher among respondents with disabilities who tested positive (40%) than among respondents without disabilities who tested positive (18%).

conclusionsOngoing symptoms among adults with and without disabilities who also test positive for SARS-CoV-2 are common; however, the frequency of health care utilization for ongoing symptoms is two-fold among adults with disabilities.

Indexed as

COVID-19Persons with DisabilitiesAdultHumansPatient Acceptance of Health CarePost-Acute COVID-19 SyndromeSARS-CoV-2Surveys and QuestionnairesCOVID-19DisabilitiesLong COVIDPost-acute sequelae of SARS-CoV-2 infectionPost-COVID conditions

Identifiers

PMID36740547
PMCPMC9762038
OpenAlexW4312056179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.